Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the major intracellular cation; it maintains intracellular tonicity, transmits nerve impulses, and contracts muscles. Dextrose provides calories and may reduce protein and nitrogen loss. Sodium chloride maintains extracellular fluid volume and tonicity.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Parenteral replenishment of fluid, electrolytes, and calories in patients unable to take orally,Maintenance of hydration and electrolyte balance,Treatment and prevention of hypokalemia
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion; rate determined by clinical need; typical adult maintenance: 100-200 m L/hour (equivalent to KCl 0.15 g/hour, dextrose 10 g/hour, sodium chloride 0.2 g/hour) based on fluid and electrolyte requirements; maximum infusion rate: KCl 10 m Eq/hour (0.75 g/hour) or 200 m L/hour, whichever is lower; do not exceed 200 m L/hour.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Potassium: 7.5 hours (distribution) with terminal half-life dependent on renal function; in normal renal function, effective half-life for potassium homeostasis is ~4-6 hours. Dextrose: Immediate metabolism; not applicable. Sodium: 12-24 hours (renal handling) but varies with sodium balance.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Potassium is excreted primarily by the kidneys; dextrose is metabolized to carbon dioxide and water; sodium chloride is excreted mainly by the kidneys.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal: >90% of potassium, dextrose (metabolized), and sodium are eliminated renally. Potassium is primarily excreted by the kidneys (90-95%) with a small fraction (5-10%) eliminated in feces. Dextrose is completely metabolized to carbon dioxide and water, with no significant biliary excretion. Sodium is excreted mainly in urine (>95%) with minimal fecal loss.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Potassium: Not significantly protein-bound (<2%). Dextrose: Not protein-bound. Sodium: Not protein-bound (<5% bound to albumin).
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Potassium: 0.67 L/kg (total body water); clinical meaning: distributes throughout extracellular and intracellular compartments, but intracellular uptake is slow. Dextrose: 0.2 L/kg (extracellular fluid). Sodium: 0.25 L/kg (extracellular fluid).
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intravenous: 100% for all components. Oral (not applicable for this formulation): N/A. IM/SC: Not recommended due to irritation.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
GFR <30 m L/min: Avoid use due to risk of hyperkalemia and fluid overload; consider alternative therapy. GFR 30-50 m L/min: Use with caution, reduce infusion rate by 50% and monitor serum potassium and renal function closely. GFR >50 m L/min: No adjustment required.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Use with caution; reduce infusion rate by 25-50% and monitor serum potassium and ammonia levels. Child-Pugh Class C: Avoid use; risk of hyperkalemia and precipitation of hepatic encephalopathy.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Weight-based: Infuse at 0.5-1 m L/kg/hour (equivalent to KCl 0.75-1.5 mg/kg/hour, dextrose 0.5-1 g/kg/hour, sodium chloride 1-2 mg/kg/hour); maximum rate: 2 m L/kg/hour; adjust based on serum electrolytes, glucose, and fluid status. Not recommended for neonates due to high dextrose concentration (10%) unless under strict monitoring.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Initiate at lower end of dosing range (e.g., 50-100 m L/hour) due to decreased renal function and higher risk of electrolyte imbalances and fluid overload; monitor serum potassium, glucose, and renal function frequently; avoid in patients with heart failure or significant renal impairment (GFR <30 m L/min).
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Potassium chloride injection concentrate must be diluted and used only in patients with severe hypokalemia; rapid infusion can cause fatal hyperkalemia.
None.
Risk of hyperkalemia, especially in patients with renal impairment or those receiving potassium-sparing diuretics,Do not administer unless solution is clear and container undamaged,Use with caution in patients with heart failure, severe renal insufficiency, or conditions predisposing to hyperkalemia,Monitor serum electrolytes, glucose, and fluid balance
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hyperkalemia,Acute dehydration,Addison's disease,Severe renal failure with oliguria/anuria,Concurrent use of potassium-sparing diuretics or ACE inhibitors (relative)
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Avoid potassium-rich foods (e.g., bananas, oranges, potatoes, spinach, salt substitutes) unless directed by your healthcare provider, as this product contains potassium. Limit high-sodium foods if hypertensive. Monitor carbohydrate intake if diabetic.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
First trimester: Potassium chloride at usual replacement doses is not associated with major malformations. Dextrose may be given as needed for maternal hypoglycemia but high doses near delivery may cause neonatal hypoglycemia. Sodium chloride at typical replacement doses is not teratogenic. Second and third trimesters: Potassium chloride is safe; however, avoid hyperkalemia as it may cause maternal cardiac effects. Dextrose infusion may cause maternal hyperglycemia and subsequent fetal hyperinsulinemia leading to neonatal hypoglycemia. Sodium chloride excess can contribute to fluid overload and hypertension. Overall, no directly teratogenic risk from these components at standard therapeutic doses.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Potassium, dextrose, and sodium are endogenous substances normally present in breast milk. Exogenous IV administration of these at standard doses is not expected to significantly increase milk concentrations. M/P ratio for potassium is approximately 0.1-0.3; dextrose is negligible; sodium is similar. Use during breastfeeding is considered compatible. However, monitor maternal electrolyte and glucose status.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No specific dose adjustment required under normal pregnancy physiology; however, increased plasma volume and glomerular filtration may warrant closer monitoring of potassium and glucose. Adjust rate based on maternal serum potassium and glucose levels.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Monitor serum potassium, glucose, and sodium levels during infusion, especially in patients with renal impairment, diabetes, or heart failure. Use with caution in patients with hyperkalemia, severe renal failure, or hyperglycemia. Infuse via central line if concentration > 0.15% KCl due to risk of phlebitis. Check compatibility with other IV additives.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This medication is used to replace fluids, sugar, and electrolytes in your body.,Tell your healthcare provider if you have kidney disease, diabetes, heart disease, or high blood pressure.,Report any symptoms like chest pain, irregular heartbeat, trouble breathing, or swelling of your hands/feet.,Do not suddenly stop receiving this infusion without medical advice.,Notify your nurse if you experience pain, redness, or swelling at the IV site.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium is the major intracellular cation; it maintains intracellular tonicity, transmits nerve impulses, and contracts muscles. Dextrose provides calories and may reduce protein and nitrogen loss. Sodium chloride maintains extracellular fluid volume and tonicity.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is: Intravenous infusion; rate determined by clinical need; typical adult maintenance: 100-200 m L/hour (equivalent to KCl 0.15 g/hour, dextrose 10 g/hour, sodium chloride 0.2 g/hour) based on fluid and electrolyte requirements; maximum infusion rate: KCl 10 m Eq/hour (0.75 g/hour) or 200 m L/hour, whichever is lower; do not exceed 200 m L/hour.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is classified as Category A/B. First trimester: Potassium chloride at usual replacement doses is not associated with major malformations. Dextrose may be given as needed for maternal hypoglycemia but high doses . ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.